Ixekizumab May Improve Renal Function in Psoriasis

Amoruso, Giuseppe Fabrizio; Nisticò, Steven Paul; Iannone, Luigi Francesco; Russo, Emilio; Rago, Giuseppe; Patruno, Cataldo; Bennardo, Luigi

doi:10.3390/healthcare9050543

Cited by 28 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the basic systemic antipsoriatic agents, acitretin and cyclosporin A are known to cause hyperlipidemia as a side effect [ 8 ]. As for biological treatment, it has become the first-line treatment in the management of moderate-to-severe psoriasis [ 63 ]. The drugs act by selectively blocking cytokines involved in psoriatic inflammation, such as IL-17 or IL-23 and TNF

[ 63 , 64 , 65 ].…”

Section: The Influence Of Systemic Antipsoriatic Agents On Lipidemiamentioning

confidence: 99%

“…As for biological treatment, it has become the first-line treatment in the management of moderate-to-severe psoriasis [ 63 ]. The drugs act by selectively blocking cytokines involved in psoriatic inflammation, such as IL-17 or IL-23 and TNF

[ 63 , 64 , 65 ]. A study assessing lipid profile in psoriatics before and during anti-TNF

treatment resulted in a significant decrease in total and LDL cholesterol concentration, with a trend regarding the elevation of HDL and a decrease in triglyceride levels [ 66 ].…”

Section: The Influence Of Systemic Antipsoriatic Agents On Lipidemiamentioning

confidence: 99%

See 1 more Smart Citation

Aberrations in Lipid Expression and Metabolism in Psoriasis

Nowowiejska

Baran

Flisiak

2021

IJMS

View full text Add to dashboard Cite

Psoriasis (PSO) is a common skin disease that affects about 1%–3% of the general population. It is a great medical, social and economic burden since PSO is associated with many comorbidities, of which the most common are cardiometabolic disorders. Psoriatic patients suffer more frequently from obesity, dyslipidemia, atherosclerosis, and nonalcoholic fatty liver disease. Research shows that lipid expression and metabolism disorders are present more often in such patients. This review focuses on a variety of aberrations in lipids in the skin, blood, and adipose tissue in psoriatic patients and their multifactorial impact on the pathogenesis of psoriasis.

show abstract

[ 63 , 64 , 65 ].…”

Section: The Influence Of Systemic Antipsoriatic Agents On Lipidemiamentioning

confidence: 99%

[ 63 , 64 , 65 ]. A study assessing lipid profile in psoriatics before and during anti-TNF

treatment resulted in a significant decrease in total and LDL cholesterol concentration, with a trend regarding the elevation of HDL and a decrease in triglyceride levels [ 66 ].…”

Section: The Influence Of Systemic Antipsoriatic Agents On Lipidemiamentioning

confidence: 99%

Aberrations in Lipid Expression and Metabolism in Psoriasis

Nowowiejska

Baran

Flisiak

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Chronic plaque-type psoriasis is the most common form of the immune-mediated inflammatory skin disease, psoriasis. Supposedly, genetic and environmental factors interplay in triggering the appearance of the characteristic red and silver scaly plaques on the skin of patients [ 1 , 2 ]. The pathomechanism of this multifactorial disease is not fully understood and with current therapeutic possibilities, recurrence of symptoms cannot yet be prevented [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Stress-Related Regulation Is Abnormal in the Psoriatic Uninvolved Skin

Bozó

Danis

Flink

et al. 2021

Life

View full text Add to dashboard Cite

Keratinocyte stress-response of the uninvolved psoriatic epidermis is known to be altered compared to healthy cells. Therefore, we aimed to reveal potential mechanisms underlying this alteration. We compared the expression of annotated cell-stress-related proteins between uninvolved psoriatic and healthy skin using the protein array method. Data were analyzed by the Reactome over-representation test. We found that p27/CDKN1B and cytochrome C showed at least a two-fold increase, while cyclooxygenase-2, indolamine-2,3-dioxygenase-1, serum paraoxonase 1, serum paraoxonase 3, serine-46-phosphorylated tumor protein p53, and superoxide-dismutase-2 showed a two-fold decrease in expression in the uninvolved skin. Over-representation analysis suggested the Forkhead-box protein O (FOXO)-mediated transcription as the most significant pathway affected by the differently expressed cell-stress-related proteins (DECSRPs). DECSRPs indicate increased FOXO-mediated transcription of cell-cycle genes and reduced interleukin-signaling in the psoriatic uninvolved skin. Nuclear positivity of the FOXO-signaling-related p27/CDKN1B and FOXO1 are negatively correlated with the disease severity and showed increased expression in the uninvolved epidermis and also in healthy primary keratinocytes, which were grown on cartilage oligomeric matrix protein-coated surfaces. Our results indicate a cell-cycle inhibitory process, as a stress-related compensatory mechanism in the uninvolved epidermis, that could be responsible for blocking keratinocyte hyperproliferation in the psoriatic uninvolved skin, thus maintaining the symptomless skin phenotype.

show abstract

“…Smoking produces free radicals that may activate signaling pathways such as the mitogen-activated kinase, nuclear factor B and Janus kinase-STAT pathways. Byproducts from smoking, such as nicotine and dioxin, activate T cells that produce interleukin-12 (IL-12), interleukin-17 (IL-17) and interleukin-23 (IL-23), which are also involved in the pathogenesis of psoriasis [ 7 , 8 ]. Because IL-17 is one of the major cytokines involved in the pathogenesis of psoriasis, there are mechanistic reasons to believe that smoking could contribute to the development of psoriasis [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital

Constantin

Bucur

Mutu

et al. 2021

JPM

View full text Add to dashboard Cite

Psoriasis is an immune-mediated chronic inflammatory skin disease with extracutaneous manifestations, that affects about 1–3% of the world’s population. The disease is not life-threatening, but the disability which comes with it is comparable to the disability caused by other serious chronic diseases, such as oncologic or cardiovascular disease. Several risk factors, such as infections, stress, smoking, excessive alcohol consumption and genetic predisposition have been involved in inducing psoriasis. Smoking status is a risk factor for many chronic diseases, including psoriasis. Moreover, recent studies have tried to answer the question of whether smoking also influences the response to biologic therapy in patients with psoriasis. Through the current study, our intention is to find out how smoking affects the response to biologic treatment. A hospital-based cross-sectional, observational, non-interventional, retrospective study of moderate and severe psoriasis patients receiving biologic treatment was developed. Two groups were defined based on smoking status: group 1 included smokers (more than 10 cigarettes/day) and former smokers, and group 2 included non-smokers. The data that resulted from the analysis of the cohort of patients demonstrate that smoking status does not affect the response of biologic therapy in patients with moderate and severe psoriasis.

show abstract

Ixekizumab May Improve Renal Function in Psoriasis

Cited by 28 publications

References 29 publications

Aberrations in Lipid Expression and Metabolism in Psoriasis

Aberrations in Lipid Expression and Metabolism in Psoriasis

Stress-Related Regulation Is Abnormal in the Psoriatic Uninvolved Skin

The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital

Contact Info

Product

Resources

About